{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-104769","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.666458+00:00","generated_at":"2026-06-10T07:38:59.741622+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avenue Therapeutics receives Nasdaq delisting notice for bid price below $1.00 for 30 consecutive days","bullets":["Received Nasdaq notice on Sept 27, 2023 for non-compliance with minimum bid price requirement (Rule 5550(a)(2)).","Common stock closed below $1.00 per share for 30 consecutive business days.","Company has 180-day grace period through March 25, 2024 to regain compliance by closing at $1.00+ for 10+ consecutive days.","If not compliant by March 25, 2024, may seek second 180-day period if it meets initial listing criteria and intends to reverse split.","Company will monitor bid price and consider options; no assurance of maintaining listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-104769","json":"https://secwatch.observer/filing/0001104659-23-104769.json","markdown":"https://secwatch.observer/filing/0001104659-23-104769.md","text":"https://secwatch.observer/filing/0001104659-23-104769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923104769/0001104659-23-104769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923104769/tm2327174d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:38:59.741622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8461efb65de0bc1aab03dd4790f174e0a8638af8","claim":"AVENUE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"September 27, 2023, Avenue Therapeutics, Inc. (the “ Company ”) received a letter from the Staff of the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the bid price of the Company’s common stock (“ Common Stock ”) had closed below $1.00 per share for 30 consecutive business days, and that, therefore, the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “ Minimum-Bid Price Requirement ”), which sets forth the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq’s notice has no i","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923104769/0001104659-23-104769-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}